Search clinical trials for: Hetrombopag

Total 221 results

Tongji Hospital

Not yet recruiting

Hetrombopag for Lower-risk MDS With Thrombocytopenia: a Prospective，Open-label, Single-arm Study.

Myelodysplastic Syndromes
Wuhan Union Hospital, China
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA

Aplastic Anemia | Primary Immune Thrombocytopenia

China
Peking Union Medical College Hospital

Not yet recruiting

Efficacy and Safety of Hetrombopag in Non-severe Aplastic Anemia

Drug Effect | Aplastic Anemia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Relative Bioavailability of Early Phase and Late Phase Hetrombopag Olamine Formulations

Bioavailability Study

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.

Chemotherapy-Induced Thrombocytopenia
RenJi Hospital
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia(CIT) in Patients With Acute Myeloid Leukemia (H-CIT-AML)

Chemotherapy-Induced Thrombocytopenia
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy.

Chemotherapy-Induced Thrombocytopenia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate Different Intervals Between Dosing and Feeding on the Pharmacokinetics

Immune Thrombocytopenia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Effect of a High-fat Meal on the Pharmacokinetics of Hetrombopag and Mass Balance Study in Healthy Subjects

Healthy

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

The Efficacy and Safety of Hetrombopag as Secondary Prevention to Chemotherapy-induced Thrombocytopenia in Patients With Gynecologic Malignancies

Chemotherapy-induced Thrombocytopenia
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Bioequivalence Study of Hetrombopag in Healthy Subjects

Sever Aplastic Anaemia

China
Jiangsu HengRui Medicine Co., Ltd.

Withdrawn

A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia

Chemotherapy-Induced Thrombocytopenia
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Trial of Hetrombopag in Healthy and Hepatic Impairment Subjects

Sever Aplastic Anaemia

China
Huazhong University of Science and Technology

Recruiting

Herombopag Olamine in the Treatment of Thrombocytopenia After Chemotherapy (hetrombopag)

Malignant Tumors of the Digestive System | Trombocitopenia

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Hetrombopag for Pediatric Patients With Chronic Immune Thrombocytopenia

Immune Thrombocytopenia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia （SAA） Patient

Severe Aplastic Anemia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Metabolism and Disposition of [14C] Herombopag in Chinese Healthy Human Subjects

Healthy

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Safety and Efficacy Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients

Chronic Idiopathic Thrombocytopenic Purpura

China
Sun Yat-sen University

Not yet recruiting

Hetrombopag in Secondary Prevention of XPO-1 Inhibitor-induced Thrombocytopenia in Lymphoma

Chemotherapy-Induced Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital

Recruiting

Hetrombopag for the Enhancement of Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation

Allogeneic Hematopoietic Stem Cell Transplantation | Hematological Disease

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients

Purpura, Thrombocytopenic, Idiopathic

China
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Chemotherapy in Advanced Breast Cancer

Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Extension Study of Hetrombopag in Severe Aplastic Anemia

Treatment-naive Severe Aplastic Anemia

China
Novartis Pharmaceuticals

Completed

A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Purpura, Thrombocytopenic, Idiopathic

Russian Federation
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Phase I Study of Hetrombopag Olamine in Healthy Adult Volunteers

Healthy

China
Second Hospital of Shanxi Medical University

Not yet recruiting

Clinical Study on the Efficacy and Safety of Hetropapa Ethanolamine Tablets in the Treatment of Thrombocytopenia Caused by Concurrent Radiotherapy and Chemotherapy in Cervical Cancer

Tumor Chemotherapy-related Thrombocytopenia

China
The First Affiliated Hospital of Zhengzhou University
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Clinical Study of Herombopag in Tumors-associated Thrombocytopenia

Tumor Therapy-related Thrombocytopenia
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Extension Study of Herombopag for Pediatric Patients With Chronic Immune Thrombocytopenia

Immune Thrombocytopenia
SuxiaLuo

Recruiting

A Real-world Study of Herombopag in the Treatment of Thrombocytopenia Related Diseases in Henan Province

Carcinoma;Blood

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient

Idiopathic Thrombocytopenic Purpura

China
Wuhan Union Hospital, China
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

Efficacy and Safety of TPO Receptor Agonists in the Treatment of Elderly ITP Patients

Primary Immune Thrombocytopenia
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Study of the Food Effects of Herombopag Olamine Tablets in Healthy Subjects

Adult Patients With Chronic Primary ITP | Adult Patients With SAA Who do Not Respond Well to Immunosuppressive Therapy
Peking Union Medical College Hospital

Not yet recruiting

A Prospective, Randomized, Controlled Study of rhTPO in Combination With Herombopag + CsA vs Herombopag + CsA for the Treatment of Primary TD-NSAA

Drug Effect | Aplastic Anemia

China
Weill Medical College of Cornell University
Novartis

Terminated

End of EXTEND: Discontinuation of Medication for Patients With Immune Thrombocytopenia

Immune Thrombocytopenia

United States
Institute of Hematology & Blood Diseases Hospital...
Xijing Hospital; Xi'an Central Hospital; The Second Hospital of Hebei Medical... and other collaborators

Active, not recruiting

A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts (TE-ITP)

Previously Treated Primary Immune Thrombocytopenia

China
Fondazione Progetto Ematologia

Completed

Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)

Chronic Lymphocytic Leukemia | Purpura, Thrombocytopenic, Idiopathic | Non Hodgkin's Lymphoma | Autoimmune Thrombocytopenia | Autoimmune Thrombocytopenic Purpura

Italy
Tel-Aviv Sourasky Medical Center
Novartis

Recruiting

Eltrombopag Treatment in Patients With Prolonged BM Toxicity After CART

B Cell Lymphoma | CART Treatment

Israel
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Eltrombopag in Second Line Adult Primary Immune Thrombosytopenia

Primacy Immune Thrombocytopenia

Italy
Novartis Pharmaceuticals

Completed

Drug Use Investigation for REVOLADE (ITP)

Purpura, Thrombocytopaenic, Idiopathic
Assiut University

Unknown

Eltrombopag in Chronic ITP

Immune Thrombocytopenia
Nanfang Hospital of Southern Medical University
Guangzhou First People's Hospital; Second Affiliated Hospital, Sun Yat-Sen... and other collaborators

Unknown

Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AML

Acute Myeloid Leukemia | Thrombocytopenia | Eltrombopag

China
IRCCS Policlinico S. Matteo

Completed

Eltrombopag for Inherited Thrombocytopenias

Inherited Platelet Disorder

Italy
Dana-Farber Cancer Institute

Terminated

Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma

Multiple Myeloma | Thrombocytopenia

United States
GlaxoSmithKline

Completed

WEUSKOP5410: Observational Study in ENABLE Clinical Trials

Hepatitis C
GlaxoSmithKline

Completed

Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Purpura (REPEAT)

Purpura, Thrombocytopaenic, Idiopathic

Germany, Russian Federation
Yin Jie

Recruiting

Herombopag + rhTPO in Severe Immune Thrombocytopenia

Immune Thrombocytopenia

China
Hebei Medical University Fourth Hospital

Not yet recruiting

A Multicentre Real-world Study of Heptapopal Ethanolamine Tablets in Concurrent/Sequential Radioimmunoinduced Thrombocytopenia

Cancer, Therapy-Related
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Study of the Food Effects of Herombopag Olamine Tablets in Healthy Subjects.

Adult Patients With Chronic Primary ITP | Adult Patients With SAA Who do Not Respond Well to Immunosuppressive Therapy

China
Novartis Pharmaceuticals

Completed

A Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia

Cytopaenia

Japan
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

The Efficacy and Safety of Hetrombopag in Primary Prevention of Thrombocytopenia Induced by the Niraparib Maintenance in Advanced Ovarian Cancer Patients

Thrombocytopenia

Search clinical trials for: Hetrombopag

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations